StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Other Residual Products (8-K Schedule) by Year

Other Residual Products (8-K Schedule) — Rest of World (ROW) ($M) ($M)

Amgen Other Residual Products (8-K Schedule): $220M in FY2025, down 4.3% from a year earlier.

Latest, FY2025
220
Period ended Dec 31, 2025
Change on a year earlier
-4.3%
230 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Other products (2) | 1,091 | 220 | 1,311 | 1,412 | (7%)”

Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Reported in Form 8-K Product Sales Detail Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Amgen Other Residual Products (8-K Schedule) ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-other-8k-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.